Form 4: Citius Oncology Director Granted Stock Options and Files Power of Attorney

Myron Z. Holubiak, a director of Citius Oncology, Inc., was granted stock options and filed a power of attorney authorizing specific individuals to act on his behalf for SEC filings.

Summary

• Myron Z. Holubiak, a director of Citius Oncology, Inc., received stock options to purchase 500,000 shares of common stock at an exercise price of $2.15 on August 12, 2024.
• These options vest over three years, starting July 5, 2023, with a portion vesting monthly for the first year and the remainder on the second and third anniversaries, contingent upon continuous service.
• The options were originally issued by Citius Oncology Sub, Inc. and assumed by Citius Oncology, Inc. following a merger transaction that closed on August 12, 2024.
• Holubiak also executed a power of attorney, effective August 13, 2024, appointing Jaime Bartushak, Alexander M. Donaldson, and Lorna A. Knick to handle SEC filings on his behalf, including Forms ID, 3, 4, 5, and Schedules 13D/13G.

Sentiment

Score: 7

Explanation: The document reflects standard corporate governance procedures and executive compensation practices, which are generally viewed neutrally to positively by investors as they align management interests with shareholders.

Positives

• The granting of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes continued service to the company.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key personnel, aligning their interests with the long-term success of the company. The use of a power of attorney for SEC filings is also a standard administrative procedure.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and executives in the biotechnology industry, similar to companies like Amgen, Gilead Sciences, and Biogen.
• The vesting schedule of three years is also typical, aligning with industry norms for incentivizing long-term commitment.
• The exercise price of $2.15 would be compared to the market price of CTOR stock at the time of the grant to assess its potential value to the recipient.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for the director.
• The power of attorney ensures timely compliance with SEC regulations.

Key Dates